You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES
  1. CORPORATE - 31-10-2017

    Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy

    Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells

    read more 
  2. CORPORATE - 25-08-2017

    Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®

    The product is approved for post-exposure prophylaxis against rabies infection

    read more 
  3. EVENTS - 14-07-2017

    Kedrion Biopharma attends XXVI ISTH Congress in Berlin, Germany

    A crowded symposium dedicated to the SIPPET Study was held on July 9th

    read more 
  4. EVENTS - 22-05-2017

    Farmindustria roadshow is hosted by Kedrion

    Innovation and Production of Value held on 19th May at our Bolognana production plant

    read more 

Pages

For more information please contact: pressoffice@kedrion.com